Background characteristics and anticoagulant usage patterns of elderly non-valvular atrial fibrillation patients in the ANAFIE registry: a prospective, multicentre, observational cohort study in Japan

Figures

• 

  Figure 1. Anticoagulant administration classified by bleeding riska in the population at high risk of stroke (CHADS2 ≥3). In each case, the proportion of patients receiving each type of treatment (warfarin, DOAC, parenteral anticoagulation, or no anticoagulation) is shown. The population of patients receiving DOAC treatment is further categorised according to the specific drug administered (dabigatran, rivaroxaban, apixaban, or edoxaban). aHigh bleeding risk is HAS-BLED ≥3; low bleeding risk is HAS-BLED ≤2. *P<0.0001 for between-group difference. DOAC, direct oral anticoagulant.

• 

  Figure 2. TTR classified by bleeding riska in the population at high risk of stroke (CHADS2 ≥3). The TTR indicates the percentage of time a patient’s INR was within the desired treatment range, and was divided into categories of <40%, ≥40% to<60%, ≥60%, or unknown. The proportions of patients within each category are shown. In addition, the category of ≥60% is further divided into ≥60% to <80% and ≥80%. aHigh bleeding risk is HAS-BLED ≥3; low bleeding risk is HAS-BLED ≤2. The overall mean TTR for each group is shown next to the y-axis. For calculation of mean values, unknowns were excluded; thus, bn=6966, cn=1444, and dn=2814. *p=0.0146 for between-group difference. INR, International Normalized Ratio; TTR, time in therapeutic range.

• 

  Figure 3. DOAC dose distribution classified by bleeding riska in the population at high risk of stroke (CHADS2 ≥3). The daily dose for each individual DOAC (dabigatran, rivaroxaban, apixaban, or edoxaban) was categorised as suboptimal (very low and unlikely to achieve the desired therapeutic effect), reduced (lower than the recommended standard dose, used particularly for elderly patients or special populations), standard (the normal recommended adult dose), or other (eg, supratherapeutic doses). The proportions of patients receiving each dose are shown. In addition, as suboptimal dosing (blue bars) may encompass several dosages, each suboptimal dose was noted, and the proportions of patients receiving the specified dose are indicated. aHigh bleeding risk is HAS-BLED ≥3; low bleeding risk is HAS-BLED ≤2. DOAC, direct oral anticoagulant.